Vicks Action 500 Extra, Phensedyl sales to resume

Image
Press Trust of India New Delhi
Last Updated : Mar 16 2016 | 8:49 PM IST
FMCG firm Procter & Gamble and pharma major Abbott will resume sales of their popular medicines 'Vicks Action 500 Extra' and cough syrup 'Phensedyl', respectively after Delhi High Court stayed government's ban on sale of their certain combination drugs.
Several companies had approached the court challenging a decision by the Health Ministry to ban over 340 fixed dose combination drugs as a result of which many popular medicines have been affected.
"The company would resume manufacture and sale of Vicks Action 500 Extra," P&G said in a statement a day after getting an interim relief from the court on the matter.
On Tuesday it had announced stopping of sales of its medicine.
According to industry sources, Abbott has also resumed sales of its cough syrup Phensedyl following the court order.
Pfizer, which was the first to announce stopping of sales of its cough syrup Corex, refused to comment on whether it has resumed sales of the medicine after getting relief from the court.
Companies including, Pfizer, Abbott Healthcare, Macleods Pharmaceuticals and Procter & Gamble, Glenmark and Reckitt Benckiser have received interim relief from the Court which stayed till March 21 the ban imposed by the government on sale of some of their fixed dose combination (FDC) medicines.
In a gazette notification on March 10, the government had, among others, banned manufacture, sale and distribution of fixed does combination of chlopheniramine maleate plus codiene syrup which is used in the cough syrups.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 16 2016 | 8:49 PM IST

Next Story